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Machine learning can use information on patients and their clinical history to help 
physicians select the antibiotics most likely to successfully treat urinary infections 
despite growing levels of resistance. 
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Recent years have seen a worrying increase in antibiotic resistance levels of many 
bacterial infections. Antibiotic resistance not only makes it difficult to treat bacterial 
infections, but also decreases the effectiveness of antibiotic prophylaxis needed for 
safe surgeries, organ transplantation and cancer treatment1. There is an urgent need 
for new effective antibiotics, however, the antibiotic development pipeline is dry. 
Without government intervention the research for new antibiotics is rarely profitable, 
which led most major pharmaceutical companies to leave the field1. It is therefore 
crucial to use the antibiotics we have at our disposal in an optimised way, to avoid the 
risks of both treatment failure and increasing resistance levels further2.  In this issue of 
Nature Medicine, Yelin et al.3 describe a strategy for combating drug resistance caused 
by mismatched antibiotic prescriptions in urinary tract infections (UTIs).  
 
Antibiotic treatment for various bacterial infections, such as UTIs, is typically started 
empirically without knowing to which antibiotics the bacteria causing the infection are 
susceptible. UTIs are one of the most common infections encountered in primary 
care4, and account for 29%-66% of antibiotic prescriptions in care home settings5. The 
bacteria causing UTIs are often carried asymptomatically in the human body and are 
therefore frequently exposed to antibiotics, including those taken to treat other 
infections6. Consequently, bacteria causing UTIs are frequently resistant to various 
commonly used antibiotics7. Physicians of UTI patients are therefore routinely faced 
with several difficult questions. Which antibiotic is most likely to cure the patient? How 
can we preserve the usefulness of antibiotics in the long term? Should published 
guidelines be followed, or is there something special about the patient that justifies a 
different course of action?  
 
Yelin et al.3 analyse data from more than 700,000 UTI cases occurring between 2007 
and 2017 in Israel, including information on the patients’ demographics, clinical 
history, and previous use of antibiotics.  The resistance of cultured bacterial pathogens 
against six antibiotics frequently prescribed against UTIs was found to be associated 
with several demographic factors, especially the age of the patient, their gender and 
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whether or not they reside in a retirement home. Many patients contracted multiple 
UTIs during the ten-year study period, in which case the resistance profiles were often 
similar between their UTIs, suggesting either relapse or reinfection from the same 
source depending on the time span. The history of antibiotic use was also found to be 
associated with resistance of the bacterial pathogen, with the strongest association 
being between use and resistance of the same antibiotic, but other less expected 
associations exist too, as has been previously noted6. There are various mechanisms by 
which use of one antibiotic may select for resistance against another unrelated 
antibiotic3,6,8.  
 
Beyond the importance for our understanding of the drivers of antimicrobial resistance 
within hosts and at the population scale8,9, the study by Yelin et al.3 has the potential 
for the application to personalised medicine. The authors applied a machine learning 
method, called gradient boosting decision trees, to derive an algorithm which takes as 
input all available information on demographic factors, previous infection history and 
antibiotic use, and returns as output a prediction for the resistance profile of a new 
infection. In machine learning, algorithms are trained to perform complex tasks by 
recognising patterns in high dimensional large datasets. In contrast to more traditional 
statistical regression techniques, no explicit relationships have to be assumed between 
input and output parameters. Because part of the recognised patterns might be due to 
random variation and specific to the training dataset, it is crucial to evaluate the 
performance of the trained model in a test dataset (Figure 1). In this study, in order to 
fairly assess the accuracy of the predictions, the model was trained using only the first 
nine years of data, so that the remaining tenth year could be used for independent 
testing. This benchmark demonstrated that the model had a strong capacity to predict 
resistance to specific antibiotics. Considering the choice between the six drugs 
frequently prescribed against UTIs, it was found that in 8.5% of cases the physicians 
had prescribed an inappropriate drug, that is one to which the infection was resistant. 
This is only slightly better than the 10% of inappropriate prescriptions that would 
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happen if the drug was chosen at random. On the other hand, by using the predictive 
computer model, the proportion of inappropriate prescription was reduced to 5%.  
 
The study by Yelin et al.3 paves the way for the use of machine learning-assisted 
decision in the prescription of antibiotics against UTIs in a way that minimises the risk 
of treatment failure. However, the model would have to be retrained separately based 
on relevant data for application to other populations and to keep up with current 
trends in resistance. The availability of such training data may be limited in some 
settings, for example in patient populations for which doctors do not routinely send 
samples for antibiotic susceptibility testing. In addition, detailed data about patients’ 
history of antibiotic use and previous test results are not always available to the 
prescribing physicians. It would be interesting to see in future work whether a model 
with less detailed input data requirements could also improve selection of antibiotics 
that are effective against UTIs. When detailed data are available for most patients, 
similar strategies could be used for the treatment of other bacterial infections, as was 
recently proposed for bloodstream infections in a hospital setting10. Accurate 
prediction of resistance against different antibiotics is directly beneficial from the point 
of view of the patients since it avoids treatment failures. It could also have additional 
long terms benefits, for example enabling the use of more targeted antibiotics, 
reducing the need to use multiple antibiotics to cure the same infection and lowering 
the risk of onward transmission2,11. All these factors would contribute to a reduction in 
the selective advantage of resistant pathogens, and since resistance often has a 
significant fitness cost, this could lead to a reduction of the overall resistance levels 
and an easing of the global threat posed by antibiotic resistance12. 
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Figure legends 
 
Figure 1. The machine learning method is first trained based on a large number of 
patient records and antibiotic resistance measurements. The resulting trained model is 
able to predict resistance profiles based on patient data, which in turn is used to select 
the antibiotic prescription most likely to succeed in curing the infection. The 
performance of this trained model is evaluated based on a separate set of patients, to 
allow for comparison between the predicted and observed resistance measurements.  
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